Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dazodalibep in Sjögren's Syndrome
NCT06104124Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2024
- Primary completion
- Jul 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 26
01
Overview
A Phase 3 trial of dazodalibep in Sjögren's syndrome, sponsored by Amgen. Started Jan 2024; status: completed.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT06104124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104124.